Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium

被引:18
作者
Bonilla, HF
Perri, MB
Kauffman, CA
Zervos, MJ
机构
[1] WILLIAM BEAUMONT HOSP,DEPT INTERNAL MED,DIV INFECT DIS,ROYAL OAK,MI 48072
[2] WAYNE STATE UNIV,SCH MED,DETROIT,MI
[3] UNIV MICHIGAN,VET AFFAIRS MED CTR,MED CTR,DEPT INTERNAL MED,DIV INFECT DIS,ANN ARBOR,MI 48109
关键词
D O I
10.1016/S0732-8893(96)00123-X
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The in vitro susceptibilities of 82 strains of vancomycin resistant Enterococcus faecium (VREF), (49 vanA and 33 van B) from over 13 hospitals in Europe and United States were studied. The MIC for several antibiotics showed high levels of resistance to vancomycin, ampicillin, gentamicin, and imipenem. All VREF strains were highly susceptible to quinupristin/dalfopristin with a MIC 90% of 0.5 mu g/ml for both vanA and vanB phenotypes. Time-kill and synergy studies of VREF for quinupristin/dalfopristin alone and quinupristin/dalfopristin in combination with several antibiotics (ampicillin, gentamicin, ciprofloxacin, rifampin and novobiocin) did not show bactericidal activity. In induction experiments using SF6550, (VREF, a vanA strain), quinupristin/dalfopristin showed a delay in the expression of vancomycin resistance by 2.5 hours. The results of this study show quinupristin/dalfopristin to have excellent in vitro activity versus multiple resistant E. faecium. (C) 1996 Elsevier Science Inc.
引用
收藏
页码:127 / 131
页数:5
相关论文
共 44 条
[1]   GENETICS AND MECHANISMS OF GLYCOPEPTIDE RESISTANCE IN ENTEROCOCCI [J].
ARTHUR, M ;
COURVALIN, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (08) :1563-1571
[2]  
AUMERCIER M, 1992, J ANTIMICROB CHEMO S, V30, pA9
[3]   IN-VITRO ACTIVITIES OF A STREPTOGRAMIN (RP59500), 3 MACROLIDES, AND AN AZALIDE AGAINST 4 RESPIRATORY-TRACT PATHOGENS [J].
BARRY, AL ;
FUCHS, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (01) :238-240
[4]  
Bonilla H., 1995, Journal of Investigative Medicine, V43, p485A
[5]   INVITRO AND INVIVO SYNERGIC ACTIVITY AND FRACTIONAL INHIBITORY CONCENTRATION (FIC) OF THE COMPONENTS OF A SEMISYNTHETIC STREPTOGRAMIN, RP 59500 [J].
BOUANCHAUD, DH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 30 :95-99
[6]   EPIDEMIOLOGIC ANALYSIS AND GENOTYPIC CHARACTERIZATION OF A NOSOCOMIAL OUTBREAK OF VANCOMYCIN-RESISTANT ENTEROCOCCI [J].
BOYLE, JF ;
SOUMAKIS, SA ;
RENDO, A ;
HERRINGTON, JA ;
GIANARKIS, DG ;
THURBERG, BE ;
PAINTER, BG .
JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (05) :1280-1285
[7]  
BRUMFITT W, 1992, J ANTIMICROB CHEMO S, V30, pA29
[8]   CLONAL SPREAD OF VANCOMYCIN-RESISTANT ENTEROCOCCUS-FAECIUM BETWEEN PATIENTS IN 3 HOSPITALS IN 2 STATES [J].
CHOW, JW ;
KURITZA, A ;
SHLAES, DM ;
GREEN, M ;
SAHM, DF ;
ZERVOS, MJ .
JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (06) :1609-1611
[9]   INVITRO ACTIVITY OF RP59500, AN INJECTABLE STREPTOGRAMIN ANTIBIOTIC, AGAINST VANCOMYCIN-RESISTANT GRAM-POSITIVE ORGANISMS [J].
COLLINS, LA ;
MALANOSKI, GJ ;
ELIOPOULOS, GM ;
WENNERSTEIN, CB ;
FERRARO, MJ ;
MOELLERING, RC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (03) :598-601
[10]  
FACKLAM RR, 1989, J CLIN MICROBIOL, V27, P735